FutureMeds GmbH

Berlin 10629

8 studies enrolling now · 14 studies all time

What they study most

Alcohol Use Disorder, Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Diseases, Chronic Kidney Disease (CKD), Depressive Disorder, Major, Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathic Pain, Diarrhea, Distal Sensory Polyneuropathy, Elevated Lp(a), Hypertension, Irritable Bowel Syndrome

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder — Recruiting now
• A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder — Recruiting now
• A Study of Brenipatide in Participants With Alcohol Use Disorder — Recruiting now
• A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) — Recruiting now
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Recruiting now
• Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension — Running, not enrolling
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy — Completed
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 — Running, not enrolling
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) — Running, not enrolling